Look—semaglutide and tirzepatide are the heavy hitters of the medical weight loss world. We haven't seen anything this effective in my thirteen years of practice. While Ozempic and Mounjaro (and their weight-loss twins Wegovy and Zepbound) share some DNA, they aren't the same drug. Picking one involves balancing your biology against your budget, and frankly, what your goals actually look like for the next six months. [1]
The quick breakdown
- Semaglutide: Just the GLP-1 hormone. It yields about 14.9% average body weight loss at 68 weeks. (2021 NEJM STEP 1 trial)
- Tirzepatide: A dual agonist (GLP-1 + GIP). It hits roughly 20.9% average weight loss at 72 weeks. (2025 NEJM head-to-head trial: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks)
- When it comes to raw power, tirzepatide wins; however, semaglutide is usually cheaper and has a much longer track record in the real world.
- Expect similar side effects—mostly just nausea or some slow digestion—which we can usually manage by tweaking your dose.
How these medications work
Semaglutide is a one-trick pony, but it's a very good trick. It activates the GLP-1 receptor, which forces your stomach to empty slower and puts a lid on that constant 'food noise' in your head. When we move to tirzepatide, things get interesting. It's a 'dual agonist' because it hits GLP-1 plus a second hormone called GIP. This combo improves your insulin sensitivity and turns up the volume on the appetite signals, which is why we consistently see those bigger numbers in our clinic's outcomes. [2]
What the clinical trials proved
Numbers don't lie. During the STEP 1 trial, patients on a 2.4 mg dose of semaglutide dropped 14.9% of their weight, compared to a measly 2.4% in the placebo group. Then tirzepatide came along. Its SURMOUNT-1 trial showed a massive 20.9% average loss at the 15 mg dose. To be blunt: the 2025 SURMOUNT-5 head-to-head trial showed tirzepatide actually outperformed semaglutide by nearly 47% in total weight lost. [3]
Side effects to watch for
I’ll be straight with you: you’re probably going to feel a little nauseous or constipated at some point. It’s almost always dose-dependent and usually clears up after a week or two once your body adjusts. Serious stuff like pancreatitis is quite rare, though we always screen patients for a personal or family history of MEN2 or medullary thyroid carcinoma first. If you've got either of those, or active pancreatitis, these meds are a no-go. [1]
Dosing and administration
- Semaglutide is a weekly tiny shot, starting at 0.25 mg and creeping up to 2.4 mg over roughly 16 weeks.
- Tirzepatide also goes once a week, but we scale it from 2.5 mg up to 15 mg across 20+ weeks.
- Don't stress the needle; it's a quick subcutaneous poke in the stomach, thigh, or arm you do yourself.
- Compounded options are great because they let us play with the dose steps to make sure you aren't feeling miserable.
The reality of cost
Insurance coverage is a headache, and brand-names will run you $900 to $1,300 monthly out of pocket. That’s why most of our Florida patients opt for compounded versions from licensed U.S. pharmacies. Semaglutide is generally the budget-friendly entry point. Tirzepatide costs a bit more to manufacture, so it’s pricier, but you’re often getting more 'bang for your buck' in terms of total weight loss per month.
How we help you choose
If you’re managing type 2 diabetes or have a significant amount of weight to lose, tirzepatide is the heavy hitter I usually recommend. It's also where we go if a patient plateaus on semaglutide. For someone just starting out with a moderate goal or a tighter budget, semaglutide is a fantastic first step. Honestly? Starting with semaglutide and switching to tirzepatide later once progress stalls is a very common—and very effective—strategy.
Maximizing your results
- Shoot for 120–140g of protein daily so you don't lose that hard-earned muscle.
- Resistance training is non-negotiable—hit the weights two or three times a week.
- Drink more water than you think you need; these drugs actually blunt your thirst signals.
- Make sure you have a clinician who actually calls you back when you’re worried about a side effect.
The final word
Neither of these is a 'magic' shortcut. They're tools—the most effective ones we've ever had—that make it possible for your brain to finally catch up with your metabolism. Tirzepatide is the powerhouse choice, while semaglutide is the accessible veteran. In the end, the 'best' one is simply the one you can stay on consistently enough to hit your target weight.
Available across Florida
Reset My Vitality is a Florida-licensed telehealth practice. The treatments covered in this guide are available to patients statewide, with medication shipped directly to your door. Explore the program for your city:
- Weight Loss in Miami, FL
- Weight Loss in Miami Beach, FL
- Weight Loss in Fort Lauderdale, FL
- Weight Loss in West Palm Beach, FL
- Weight Loss in Boca Raton, FL
- Weight Loss in Orlando, FL
- Weight Loss in Tampa, FL
- Weight Loss in Jacksonville, FL
- Weight Loss in Naples, FL
Key Clinical Studies
A short, responsible summary of recent peer-reviewed research relevant to this topic. This is for education only, not medical advice.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine · 2021
Key finding: In a randomized controlled trial, participants on semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight at 68 weeks vs 2.4% on placebo, with 86% achieving at least 5% loss.
Why it matters: Establishes the efficacy of semaglutide for substantial, sustained weight loss when paired with lifestyle support.
View studyTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 2022
Key finding: Participants on tirzepatide 15 mg lost up to 20.9% of body weight at 72 weeks vs 3.1% on placebo, with 91% achieving at least 5% loss.
Why it matters: Shows the strong average results possible with the dual GLP-1/GIP agonist tirzepatide for eligible patients.
View studyTwo-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Nature Medicine · 2022
Key finding: A 104-week trial found mean weight loss of 15.2% with semaglutide vs 2.6% with placebo, with weight loss largely maintained over two years on treatment.
Why it matters: Demonstrates long-term durability of GLP-1 weight loss when therapy is continued under clinical supervision.
View studyScientific References
Peer-reviewed studies and reviews cited in this article.
- [1]Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. View study
- [2]Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. View study
- [3]Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. View study
